company background image
1061

Essex Bio-Technology SEHK:1061 Stock Report

Last Price

HK$3.52

Market Cap

HK$2.0b

7D

-0.3%

1Y

-42.8%

Updated

19 Aug, 2022

Data

Company Financials +
1061 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance4/6
Financial Health5/6
Dividends4/6

1061 Stock Overview

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally.

Essex Bio-Technology Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Essex Bio-Technology
Historical stock prices
Current Share PriceHK$3.52
52 Week HighHK$6.78
52 Week LowHK$3.23
Beta0.55
1 Month Change-4.87%
3 Month Change-8.09%
1 Year Change-42.76%
3 Year Change-32.44%
5 Year Change-17.76%
Change since IPO255.56%

Recent News & Updates

Jun 22
Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Is Essex Bio-Technology (HKG:1061) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

May 02
Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology (HKG:1061) Has Announced That It Will Be Increasing Its Dividend To HK$0.055

Essex Bio-Technology Limited's ( HKG:1061 ) dividend will be increasing to HK$0.055 on 20th of May. This makes the...

Shareholder Returns

1061HK BiotechsHK Market
7D-0.3%-3.2%-0.9%
1Y-42.8%-51.0%-19.7%

Return vs Industry: 1061 exceeded the Hong Kong Biotechs industry which returned -51% over the past year.

Return vs Market: 1061 underperformed the Hong Kong Market which returned -19.7% over the past year.

Price Volatility

Is 1061's price volatile compared to industry and market?
1061 volatility
1061 Average Weekly Movement5.1%
Biotechs Industry Average Movement7.8%
Market Average Movement6.5%
10% most volatile stocks in HK Market12.9%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 1061 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 1061's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19901,379Haizhou Fanghttps://www.essexbio.com

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People’s Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration.

Essex Bio-Technology Fundamentals Summary

How do Essex Bio-Technology's earnings and revenue compare to its market cap?
1061 fundamental statistics
Market CapHK$1.96b
Earnings (TTM)HK$345.97m
Revenue (TTM)HK$1.64b

5.8x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1061 income statement (TTM)
RevenueHK$1.64b
Cost of RevenueHK$241.89m
Gross ProfitHK$1.40b
Other ExpensesHK$1.05b
EarningsHK$345.97m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.60
Gross Margin85.23%
Net Profit Margin21.13%
Debt/Equity Ratio32.3%

How did 1061 perform over the long term?

See historical performance and comparison

Dividends

3.1%

Current Dividend Yield

16%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is 1061 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1061?

Other financial metrics that can be useful for relative valuation.

1061 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.1x
Enterprise Value/EBITDA4.4x
PEG Ratio0.3x

Price to Earnings Ratio vs Peers

How does 1061's PE Ratio compare to its peers?

1061 PE Ratio vs Peers
The above table shows the PE ratio for 1061 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average52.5x
775 CK Life Sciences Int'l. (Holdings)
55.1xn/aHK$7.0b
1530 3SBio
6.5x6.6%HK$12.5b
6826 Shanghai Haohai Biological Technology
14.3x20.6%HK$14.2b
9995 RemeGen
133x80.0%HK$32.3b
1061 Essex Bio-Technology
5.8x21.1%HK$2.0b

Price-To-Earnings vs Peers: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the peer average (52.5x).


Price to Earnings Ratio vs Industry

How does 1061's PE Ratio compare vs other companies in the Asian Biotechs Industry?

Price-To-Earnings vs Industry: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the Hong Kong Biotechs industry average (12.1x)


Price to Earnings Ratio vs Fair Ratio

What is 1061's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1061 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.8x
Fair PE Ratio11.7x

Price-To-Earnings vs Fair Ratio: 1061 is good value based on its Price-To-Earnings Ratio (5.8x) compared to the estimated Fair Price-To-Earnings Ratio (11.7x).


Share Price vs Fair Value

What is the Fair Price of 1061 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1061 (HK$3.52) is trading above our estimate of fair value (HK$2.27)

Significantly Below Fair Value: 1061 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Essex Bio-Technology forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

5/6

Future Growth Score 5/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


21.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1061's forecast earnings growth (21.1% per year) is above the savings rate (1.6%).

Earnings vs Market: 1061's earnings (21.1% per year) are forecast to grow faster than the Hong Kong market (17.2% per year).

High Growth Earnings: 1061's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1061's revenue (17% per year) is forecast to grow faster than the Hong Kong market (10.1% per year).

High Growth Revenue: 1061's revenue (17% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1061's Return on Equity is forecast to be high in 3 years time (29.6%)


Discover growth companies

Past Performance

How has Essex Bio-Technology performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 1061 has high quality earnings.

Growing Profit Margin: 1061's current net profit margins (21.1%) are lower than last year (22.4%).


Past Earnings Growth Analysis

Earnings Trend: 1061's earnings have grown by 15.9% per year over the past 5 years.

Accelerating Growth: 1061's earnings growth over the past year (58%) exceeds its 5-year average (15.9% per year).

Earnings vs Industry: 1061 earnings growth over the past year (58%) exceeded the Biotechs industry 7.5%.


Return on Equity

High ROE: 1061's Return on Equity (19.9%) is considered low.


Discover strong past performing companies

Financial Health

How is Essex Bio-Technology's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 1061's short term assets (HK$1.5B) exceed its short term liabilities (HK$689.6M).

Long Term Liabilities: 1061's short term assets (HK$1.5B) exceed its long term liabilities (HK$439.6M).


Debt to Equity History and Analysis

Debt Level: 1061 has more cash than its total debt.

Reducing Debt: 1061's debt to equity ratio has increased from 28.7% to 32.3% over the past 5 years.

Debt Coverage: 1061's debt is well covered by operating cash flow (73.1%).

Interest Coverage: 1061 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Essex Bio-Technology current dividend yield, its reliability and sustainability?

Dividend Score

4/6

Dividend Score 4/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.12%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: 1061's dividend (3.12%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.87%).

High Dividend: 1061's dividend (3.12%) is low compared to the top 25% of dividend payers in the Hong Kong market (8.33%).


Stability and Growth of Payments

Stable Dividend: 1061's dividend payments have been volatile in the past 10 years.

Growing Dividend: 1061's dividend payments have increased over the past 10 years.


Earnings Payout to Shareholders

Earnings Coverage: With its low payout ratio (15.8%), 1061's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: With its reasonably low cash payout ratio (40.9%), 1061's dividend payments are well covered by cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

21.6yrs

Average management tenure


CEO

Haizhou Fang (56 yo)

no data

Tenure

HK$2,477,422

Compensation

Mr. Haizhou Fang serves as the Managing Director and Executive Director of Essex Bio-Technology Limited and served as its General Manager. Mr. Fang is qualified as a Senior Pharmaceutical Engineer (Profess...


CEO Compensation Analysis

Compensation vs Market: Insufficient data to establish whether Haizhou's total compensation is reasonable compared to companies of similar size in the Hong Kong market.

Compensation vs Earnings: Haizhou's compensation has increased by more than 20% in the past year.


Leadership Team

Experienced Management: 1061's management team is seasoned and experienced (21.6 years average tenure).


Board Members

Experienced Board: 1061's board of directors are seasoned and experienced ( 17.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Essex Bio-Technology Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Essex Bio-Technology Limited
  • Ticker: 1061
  • Exchange: SEHK
  • Founded: 1990
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: HK$1.959b
  • Shares outstanding: 572.95m
  • Website: https://www.essexbio.com

Number of Employees


Location

  • Essex Bio-Technology Limited
  • No. 88 Keji 6th Road
  • Hi-Tech Zone
  • Zhuhai
  • Guangdong Province
  • China

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/19 00:00
End of Day Share Price2022/08/19 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.